25 February 2016 - Gilead Sciences today announced that the company’s marketing authorization application for tenofovir alafenamide fumarate (TAF) 25 mg – an investigational, once-daily treatment for adults with chronic hepatitis B virus infection – has been fully validated and is now under assessment by the EMA.

For more details, go to: http://www.gilead.com/news/press-releases/2016/2/european-medicines-agency-validates-gileads-marketing-application-for-tenofovir-alafenamide-taf-for-the-treatment-of-chronic-hepatitis-b